1. Home
  2. PRTA vs KTF Comparison

PRTA vs KTF Comparison

Compare PRTA & KTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.15

Market Cap

429.2M

Sector

Health Care

ML Signal

N/A

Logo DWS Municipal Income Trust

KTF

DWS Municipal Income Trust

SELL

Current Price

$8.24

Market Cap

361.2M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
PRTA
KTF
Founded
2012
1988
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
429.2M
361.2M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
PRTA
KTF
Price
$8.15
$8.24
Analyst Decision
Buy
Analyst Count
7
0
Target Price
★ $21.40
N/A
AVG Volume (30 Days)
★ 420.1K
210.7K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
★ 3.54%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 0.39
Revenue
★ $814,000.00
N/A
Revenue This Year
$775.41
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$21.13
Revenue Growth
N/A
★ N/A
52 Week Low
$7.70
$7.95
52 Week High
$11.80
$9.33

Technical Indicators

Market Signals
Indicator
PRTA
KTF
Relative Strength Index (RSI) 45.82 52.03
Support Level $8.01 $7.96
Resistance Level $9.14 $8.27
Average True Range (ATR) 0.44 0.05
MACD -0.01 0.01
Stochastic Oscillator 37.55 63.16

Price Performance

Historical Comparison
PRTA
KTF

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About KTF DWS Municipal Income Trust

DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.

Share on Social Networks: